Changes in intravenous immunoglobulin prescribing patterns during a period of severe product shortages, 1995-2000

Vox Sanguinis

Volumn 89, Issue 3, 2005, Pages 150-160

  Pendergrast, Jacob M ^a   Sher, G D ^b   Callum, J L ^b  

^a CANADIAN BLOOD SERVICES   (Canada)

^b NONE

Author keywords

Canada; IVIG; Prescribing patterns; Rationing

Indexed keywords

IMMUNOGLOBULIN;

ARTICLE; BONE MARROW TRANSPLANTATION; CLINICAL PRACTICE; DOSE RESPONSE; DRUG INDUSTRY; DRUG MARKETING; DRUG SURVEILLANCE PROGRAM; DRUG USE; HEMATOLOGIC DISEASE; HUMAN; HYPOGAMMAGLOBULINEMIA; INFECTION; NEUROLOGIC DISEASE; PRESCRIPTION; PRIORITY JOURNAL; SKIN DISEASE;

ADULT; AGED; BLOOD BANKS; CANADA; DATA COLLECTION; DRUG UTILIZATION; DRUG UTILIZATION REVIEW; FEMALE; GUIDELINE ADHERENCE; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; MALE; MIDDLE AGED; PHARMACIES; PHYSICIAN'S PRACTICE PATTERNS; PRESCRIPTIONS, DRUG; RETROSPECTIVE STUDIES;

EID: 25144474955     PISSN: 00429007     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1423-0410.2005.00670.x     Document Type: Article

References (36)

1. Imbach P, Barandun S, d'Apuzzo V, Baumgartner C, Hirt A, Morell A, Rossi E, Schöni M, Vest M, Wagner HP: High dose intravenous gammaglobulin for idiopathic thrombocytopenia in childhood. Lancet 1981; 1:1228-1231
2. Medical Research Bureau Inc.: The Worldwide Plasma Fractions Market. Available at http://www.marketingresearchbureau.com/markets.html # [Accessed January 13 2005]
3. Boulis A, Goold S, Ubel PA: Responding to the immunoglobulin shortage: a case study. J Health Polit Policy Law 2002; 27:977-999
4. National Blood Safety Council: Open Forum on Shortages of Intravenous Immune Globulins and Other Plasma Products. Montreal, January 1999. Available at http://www.bloodsafety.gc.ca/docs/1999/proc/01/sum_0199-e.html [Accessed January 13 2005]
5. Sibbald B: Does Canada face a crisis? US considers ending plasma exports. CMAJ 1998; 158:1639-1641
6. Centers for Disease Control and Prevention: Outbreak of hepatitis C associated with intravenous immunoglobulin administration, United States, October 1993-June 1994. JAMA 1994; 272:424-425
7. Bresee JS, Mast EE, Coleman PJ, Baron MJ, Schonberger LB, Alter MJ, Jonas MM, Yu MY, Renzi PM, Schneider LC: Hepatitis C virus infection associated with administration of intravenous immune globulin. A cohort study. JAMA 1996; 276:1563-1567
8. US General Accounting Office: Plasma Product Risks are Low if Good Manufacturing Practices are Followed. September 1998. Available at http://www.gao.gov/archive/1998/he98205.pdf [Accessed January 13 2005]
9. National Blood Safety Council: Open Forum on Plasma Self Sufficiency. Plasma Collection and Manufacture: The Situation in Canada. Vancouver, March 2001. Available at http://www.bloodsafety.gc.ca/news/2001/gspss.ppt [Accessed January 13 2005]
10. Canadian Blood Services: IVIG Use Per Capital. Available at http://www.bloodservices.ca/CentreApps/Internet/UW_V502_MainEngine.nsf/ resources/Hospital+Section/$file/IGIV+facts+for+2004+CL.ppt [Accessed January 13 2005]
11. Canadian Blood Services: A Report to Canadians 2003/2004. Available at http://www.bloodservices.ca/CentreApps/Internet/UW_V502_MainEngine.nsf/page/ E_AR2004?OpenDocument [Accessed January 13 2005]
12. Hume H: Customer Letter #2004-08, Availability of IVIG Products for 2004-2005. Canadian Blood Services. April 29, 2004. Available at http://www.bloodservices.ca/CentreApps/Internet/UW_V502_MainEngine.nsf/ resources/Customer+Letters/$file/CL+2004-08_E.pdf [Accessed January 13 2005]
13. Canadian Blood Services: Prescribing WIG: Prioritizing Use and Optimizing Practice. Proceedings of a Consensus Conference, Toronto, October 2000
14. British Columbia Provincial Blood Coordinating Office: The Effect of a Province-Wide Utilization Management Program on IVIG Use in British Columbia. Available at http://www. bloodlink.bc.ca/documents/ISB TIVIG presentation.ppt [Accessed January 13 2005]
15. Hanna K, Poulin-Costello M, Preston M, Maresky N: Intravenous immune globulin use in Canada. Can J Clin Pharmacol 2003; 10:11-16
16. Chan H, Heddle N: Analysis of dosing variability of IVIG in community and teaching hospitals [abstract]. Blood 2004; 104:2726
17. Gajewski LK, Bailey EM, Brown PD, Chandrasekar PH: Immune globulin use at a multihospital medical center: Am J Hosp Pharm 1994; 51:801-805
18. Lee YC, Woodfield DG, Douglas R: Clinical usage of intravenous immunoglobulins in Auckland. N Z Med J 1998; 111:48-50
19. Chen C, Danekas LH, Ratko TA, Vlasses PH, Matuszewski KA: A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centres. A multicenter drug use surveillance of intravenous immunoglobulin utilization in US academic health centers. Ann Pharmacother 2000; 34:295-299
20. Australia Blood and Blood Products Committee: Review of the Use and Supply of Intravenous Immunoglobulins in Australia. June 2000. Available at http://www.transfuse.com.au/FILES/RESOURCE/Use and Supply of IVIG in Aust.pdf [Accessed January 13 2005]
21. Farrugia A, Poulis P: Intravenous immunoglobulin: regulatory perspectives on use and supply. Transfus Med 2001; 11:63-74
22. Health Canada: Notice to Stakeholders - Guidance for Sponsors: Regulatory Requirements for Intravenous Immunoglobulin (IVIG) Products in Canada. August 18, 2004. Available at http://www.hc-sc.gc.ca/hpfb-dgpsa/bgtd-dpbtg/ivig_e.html [Accessed January 13 2005]
23. Ratko TA, Burnett DA, Foulke GE, Matuszewski KA, Sacher RA: Recommendations for off-label use of intravenously administered immunoglobulin preparations. University Hospital Consortium Expert Panel for Off-Label Use of Polyvalent Intravenously Administered Immunoglobulin Preparations. JAMA 1995; 273:1865-1870
24. Present and Future Users of IVIG: A Canadian Multidisciplinary Consensus Building Initiative. Can J Allergy Clin Immunol 1997; 5:176-208
25. Bril V, Allenby K, Midroni G, O'Connor PW, Vajsar J: IGIV in neurology - evidence and recommendations. Can J Neurol Sci 1999; 26:139-152
26. Kaul R, McGeer A, Norrby-Teglund A, Kotb M, Schwartz B, O'Rourke K, Talbot J, Low DE: Intravenous immunoglobulin therapy for streptococcal toxic shock syndrome - a comparative observational study. The Canadian Streptococcal Study Group. Clin Infect Dis 1999; 28:800-807
27. McKie J, Richardson J: The rule of rescue. Soc Sci Med 2003; 56:2407-2419
28. Pierard GE: [The costs of empiric and intuitive diagnoses. A critical evaluation of therapeutic trials and on unconventional practices]. Rev Medical Liege 1998; 53:249-251 [French]
29. Goodnough LT: The transfusion medicine specialist and utilization review. Transfus Sci 1998; 19:65-67
30. Mydlarski PR, Mittmann N, Shear NH: Intravenous immunoglobulin: use in dermatology. Skin Ther Lett 2004; 9:1-6
31. Ancona KG, Parker RI, Atlas MP, Prakash D: Randomized trial of high-dose methylprednisolone versus intravenous immunoglobulin for the treatment of acute idiopathic thrombocytopenic purpura in children. J Pediatr Hematol Oncol 2002; 24:540-544
32. Godeau B, Chevret S, Varet B, Lefrere F, Zini JM, Bassompierre F, Chèze S, Legouffe E, Hulin C, Grange MJ, Fain O, Bierling P: French ATIP Study Group. Intravenous immunoglobulin or high-dose methylprednisolone, with or without oral prednisone, for adults with untreated severe autoimmune thrombocytopenic purpura: a randomised, multicentre trial. Lancet 2002; 359:23-29
33. Nagpal S, Benstead T, Shumak K, Rock G, Brown M, Anderson DR: Treatment of Guillain-Barre syndrome: a cost-effectiveness analysis. J Clin Apheresis 1999; 14:107-113
34. Krever H: Final Report. Commission of Inquiry on the Blood System in Canada. Available at http://collection.nlc-bnc.ca/100/200/301/hcan-scan/ commission_blood_final_rep-e/ [Accessed January 2005]
35. Wilson K, Hebert PC: The challenge of an increasingly expensive blood system. CMAJ 2003; 168:1149-1150
36. Siragam V, Brinc D, Crow AR, Song S, Freedman J, Lazarus AH: Canadian antibodies with specificity for soluble antigens mimic the therapeutic effects of intravenous IgG in the treatment of autoimmune disease? J Clin Invest 2005; 115:155-160